

Edgar Filing: MGC DIAGNOSTICS Corp - Form 10-Q

MGC DIAGNOSTICS Corp

Form 10-Q

June 13, 2017

mgcd --10-31 MGC DIAGNOSTICS Corp 2017 false Q2 0000815093 0000815093 2015-10-31 0000815093  
mgcd:MgcDiagnosticsCorporationVersusGuyMartinotAndJeanBenoitMartinotMember 2015-11-01 2015-11-30  
0000815093 mgcd:MgcDiagnosticsCorporationVersusGuyMartinotAndJeanBenoitMartinotMember 2015-05-01  
2015-05-31 0000815093 mgcd:DirectorStockAwardsInLieuOfCashRetainerFeesMember 2016-02-01 2016-04-30  
0000815093 mgcd:NeurovirtualUsaInc.VersusMgcDiagnosticsCorporationMember 2016-06-01 2016-06-30  
0000815093 2016-10-31 0000815093 us-gaap:ServiceAgreementsMember 2016-10-31 0000815093  
mgcd:InstallationAndTrainingMember 2016-10-31 0000815093 mgcd:AdvancePaymentFromCustomersMember  
2016-10-31 0000815093 us-gaap:DevelopedTechnologyRightsMember 2016-10-31 0000815093  
mgcd:CustomerAndDistributorRelationshipsMember 2016-10-31 0000815093  
us-gaap:TrademarksAndTradeNamesMember 2016-10-31 0000815093 us-gaap:SoftwareDevelopmentMember  
2016-10-31 0000815093 mgcd:CapitalizedSoftwareInProgressMember 2016-10-31 0000815093 country:US  
2016-10-31 0000815093 us-gaap:EuropeMember 2016-10-31 0000815093  
mgcd:EmployeeStockPurchasePlanMember 2016-07-01 2016-12-31 0000815093  
mgcd:EmployeeStockPurchasePlanMember 2016-12-31 0000815093 us-gaap:DomesticCountryMember 2016-10-31  
0000815093 2015-11-01 2016-10-31 0000815093 us-gaap:ForeignCountryMember 2016-10-31 0000815093  
2016-12-15 2016-12-15 0000815093 2016-02-01 2016-04-30 0000815093  
mgcd:NeurovirtualUsaInc.VersusMgcDiagnosticsCorporationMember 2016-02-01 2016-04-30 0000815093  
mgcd:NeurovirtualUsaInc.VersusMgcDiagnosticsCorporationMember 2016-08-01 2016-10-31 0000815093  
mgcd:TermLoanMember 2014-07-24 0000815093 us-gaap:RevolvingCreditFacilityMember 2014-07-24 0000815093  
2017-01-24 2017-01-25 0000815093 2017-06-06 0000815093 2016-11-01 2017-04-30 0000815093 2017-04-30  
0000815093 2015-11-01 2016-04-30 0000815093 2016-04-30 0000815093 us-gaap:MinimumMember 2016-11-01  
2017-04-30 0000815093 us-gaap:MaximumMember 2016-11-01 2017-04-30 0000815093  
us-gaap:SoftwareDevelopmentMember 2016-11-01 2017-04-30 0000815093 us-gaap:SoftwareDevelopmentMember  
us-gaap:MaximumMember 2016-11-01 2017-04-30 0000815093 us-gaap:ServiceAgreementsMember 2017-04-30  
0000815093 mgcd:InstallationAndTrainingMember 2017-04-30 0000815093  
mgcd:AdvancePaymentFromCustomersMember 2017-04-30 0000815093 mgcd:ExercisePrice1Member 2017-04-30  
0000815093 mgcd:ExercisePrice1Member 2016-11-01 2017-04-30 0000815093 mgcd:ExercisePrice3Member  
2017-04-30 0000815093 mgcd:ExercisePrice3Member 2016-11-01 2017-04-30 0000815093  
mgcd:ExercisePrice4Member 2017-04-30 0000815093 mgcd:ExercisePrice4Member 2016-11-01 2017-04-30  
0000815093 mgcd:ExercisePrice5Member 2017-04-30 0000815093 mgcd:ExercisePrice5Member 2016-11-01  
2017-04-30 0000815093 mgcd:ExercisePrice6Member 2017-04-30 0000815093 mgcd:ExercisePrice6Member  
2016-11-01 2017-04-30 0000815093 mgcd:ExercisePrice7Member 2017-04-30 0000815093  
mgcd:ExercisePrice7Member 2016-11-01 2017-04-30 0000815093 mgcd:ExercisePrice8Member 2017-04-30  
0000815093 mgcd:ExercisePrice8Member 2016-11-01 2017-04-30 0000815093 mgcd:ExercisePrice9Member  
2017-04-30 0000815093 mgcd:ExercisePrice9Member 2016-11-01 2017-04-30 0000815093  
us-gaap:RestrictedStockMember 2017-04-30 0000815093 us-gaap:RestrictedStockMember 2016-11-01 2017-04-30  
0000815093 us-gaap:CostOfSalesMember 2016-11-01 2017-04-30 0000815093  
us-gaap:SellingAndMarketingExpenseMember 2016-11-01 2017-04-30 0000815093  
us-gaap:GeneralAndAdministrativeExpenseMember 2016-11-01 2017-04-30 0000815093  
us-gaap:ResearchAndDevelopmentExpenseMember 2016-11-01 2017-04-30 0000815093  
us-gaap:CostOfSalesMember 2015-11-01 2016-04-30 0000815093 us-gaap:SellingAndMarketingExpenseMember  
2015-11-01 2016-04-30 0000815093 us-gaap:GeneralAndAdministrativeExpenseMember 2015-11-01 2016-04-30  
0000815093 us-gaap:ResearchAndDevelopmentExpenseMember 2015-11-01 2016-04-30 0000815093  
mgcd:EmployeeStockPurchasePlanMember 2017-04-30 0000815093 mgcd:EmployeeStockPurchasePlanMember  
2016-11-01 2017-04-30 0000815093 mgcd:DirectorStockAwardsInLieuOfCashRetainerFeesMember 2015-11-01  
2016-04-30 0000815093 us-gaap:DevelopedTechnologyRightsMember 2017-04-30 0000815093  
mgcd:CustomerAndDistributorRelationshipsMember 2017-04-30 0000815093  
us-gaap:TrademarksAndTradeNamesMember 2017-04-30 0000815093 us-gaap:SoftwareDevelopmentMember

Edgar Filing: MGC DIAGNOSTICS Corp - Form 10-Q

2017-04-30 0000815093 mgcd:CapitalizedSoftwareInProgressMember 2017-04-30 0000815093  
us-gaap:SoftwareDevelopmentMember 2017-02-01 2017-04-30 0000815093 us-gaap:SoftwareDevelopmentMember  
2016-02-01 2016-04-30 0000815093 us-gaap:SoftwareDevelopmentMember 2015-11-01 2016-04-30 0000815093  
us-gaap:FiniteLivedIntangibleAssetsMember 2016-11-01 2017-04-30 0000815093  
us-gaap:FiniteLivedIntangibleAssetsMember 2015-11-01 2016-04-30 0000815093 mgcd:TermLoanMember  
2016-11-01 2017-04-30 0000815093 country:US 2017-02-01 2017-04-30 0000815093 us-gaap:AmericasMember  
2017-02-01 2017-04-30 0000815093 mgcd:EuropeMiddleEastAfricaMember 2017-02-01 2017-04-30 0000815093  
us-gaap:AsiaPacificMember 2017-02-01 2017-04-30 0000815093 2017-02-01 2017-04-30 0000815093 country:US  
2016-02-01 2016-04-30 0000815093 us-gaap:AmericasMember 2016-02-01 2016-04-30 0000815093  
mgcd:EuropeMiddleEastAfricaMember 2016-02-01 2016-04-30 0000815093 us-gaap:AsiaPacificMember  
2016-02-01 2016-04-30 0000815093 country:US 2016-11-01 2017-04-30 0000815093 us-gaap:AmericasMember  
2016-11-01 2017-04-30 0000815093 mgcd:EuropeMiddleEastAfricaMember 2016-11-01 2017-04-30 0000815093  
us-gaap:AsiaPacificMember 2016-11-01 2017-04-30 0000815093 country:US 2015-11-01 2016-04-30 0000815093  
us-gaap:AmericasMember 2015-11-01 2016-04-30 0000815093 mgcd:EuropeMiddleEastAfricaMember 2015-11-01  
2016-04-30 0000815093 us-gaap:AsiaPacificMember 2015-11-01 2016-04-30 0000815093 country:US 2017-04-30  
0000815093 us-gaap:EuropeMember 2017-04-30 0000815093  
mgcd:DirectorStockAwardsInLieuOfCashRetainerFeesMember 2017-02-01 2017-04-30 0000815093  
us-gaap:CostOfSalesMember 2016-02-01 2016-04-30 0000815093 us-gaap:SellingAndMarketingExpenseMember  
2016-02-01 2016-04-30 0000815093 us-gaap:GeneralAndAdministrativeExpenseMember 2016-02-01 2016-04-30  
0000815093 us-gaap:ResearchAndDevelopmentExpenseMember 2016-02-01 2016-04-30 0000815093  
us-gaap:CostOfSalesMember 2017-02-01 2017-04-30 0000815093 us-gaap:SellingAndMarketingExpenseMember  
2017-02-01 2017-04-30 0000815093 us-gaap:GeneralAndAdministrativeExpenseMember 2017-02-01 2017-04-30  
0000815093 us-gaap:ResearchAndDevelopmentExpenseMember 2017-02-01 2017-04-30 0000815093  
mgcd:DirectorStockAwardsInLieuOfCashRetainerFeesMember 2016-11-01 2017-04-30 0000815093 2017-04-02  
2017-04-03 0000815093 2017-02-01 2017-02-02 0000815093 mgcd:ExercisePrice10Member 2017-04-30  
0000815093 mgcd:ExercisePrice10Member 2016-11-01 2017-04-30 0000815093 mgcd:ExercisePrice11Member  
2017-04-30 0000815093 mgcd:ExercisePrice11Member 2016-11-01 2017-04-30 0000815093  
us-gaap:SubsequentEventMember 2017-05-01 2017-05-01 0000815093 us-gaap:SubsequentEventMember  
2017-05-01 0000815093 us-gaap:DomesticCountryMember 2016-11-01 2017-04-30 0000815093  
mgcd:MedisoftSAMedisoftRAMItaliaSrlMember 2017-04-30 0000815093 us-gaap:MaximumMember  
mgcd:SoftwareMember 2016-11-01 2017-04-30 0000815093 mgcd:MgcDiagnosticsBelgiumS.p.r.l.Member  
2017-02-01 2017-04-30 0000815093 mgcd:MgcDiagnosticsBelgiumS.p.r.l.Member 2016-11-01 2017-04-30  
0000815093 mgcd:MgcDiagnosticsBelgiumS.p.r.l.Member 2016-02-01 2016-04-30 0000815093  
mgcd:MgcDiagnosticsBelgiumS.p.r.l.Member 2015-11-01 2016-04-30 0000815093  
mgcd:NeurovirtualUsaInc.VersusMgcDiagnosticsCorporationMember 2017-04-30 0000815093  
us-gaap:FiniteLivedIntangibleAssetsMember 2017-02-01 2017-04-30 0000815093  
us-gaap:FiniteLivedIntangibleAssetsMember 2016-02-01 2016-04-30 xbrli:shares xbrli:pure iso4217:EUR  
iso4217:USD iso4217:USD xbrli:shares mgcd:item

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

# FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the quarterly period ended April 30, 2017.

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File Number 001-13543

## MGC DIAGNOSTICS CORPORATION

(Exact name of registrant as specified in its charter)

**Minnesota**

(State or other jurisdiction of incorporation or organization)

**41-1579150**

(IRS Employer Identification No.)

**350 Oak Grove Parkway, Saint Paul, Minnesota 55127-8599**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(651) 484-4874**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes      No

Edgar Filing: MGC DIAGNOSTICS Corp - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes          No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “accelerated filer,” “large accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated Filer  
Smaller Reporting Company

Accelerated Filer  
Emerging Growth Company

Non-Accelerated Filer

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act:

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes  
No

As of June 6, 2017, the Company had outstanding 4,440,134 shares of Common Stock, \$0.10 par value.

---

**TABLE OF CONTENTS**

|  |    |
|--|----|
| <u>PART I – FINANCIAL INFORMATION</u>  | 3  |
| <u>Item 1. Financial Statements.</u>   | 3  |
| <u>Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operation.</u> | 15 |
| <u>Item 3. Quantitative and Qualitative Disclosures About Market Risk.</u>                           | 21 |
| <u>Item 4. Controls and Procedures.</u>  | 22 |
| <u>PART II – OTHER INFORMATION</u>   | 24 |
| <u>Item 1. Legal Proceedings.</u>  | 24 |
| <u>Item 1A. Risk Factors.</u>  | 24 |
| <u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</u>                          | 24 |
| <u>Item 3. Default Upon Senior Securities.</u>   | 24 |
| <u>Item 4. Mine Safety Disclosure.</u>   | 24 |
| <u>Item 5. Other Information.</u>  | 24 |
| <u>Item 6. Exhibits.</u>   | 25 |
| <u>SIGNATURES</u>  | 26 |

Table of Contents**PART I – FINANCIAL INFORMATION****Item 1. Financial Statements.****MGC DIAGNOSTICS CORPORATION AND SUBSIDIARIES****Consolidated Balance Sheets****April 30, 2017 and October 31, 2016**

(In thousands, except share and per share data)

|   | <b>April 30,<br/>2017</b> | <b>October 31,<br/>2016</b> |
|---|---------------------------|-----------------------------|
|   | (Unaudited)               |                             |
| <b>Assets</b>   |                           |                             |
| <b>Current Assets:</b>  |                           |                             |
| Cash  | \$ 4,957                  | \$ 7,265                    |
| Accounts receivable, net of allowance for doubtful accounts of \$174 and \$92, respectively   | 6,352                     | 8,286                       |
| Inventories, net of obsolescence reserve of \$1,293 and \$1,281, respectively   | 5,034                     | 4,916                       |
| Prepaid expenses and other current assets   | 537                       | 586                         |
| Total current assets  | 16,880                    | 21,053                      |
| Property and equipment, net of accumulated depreciation of \$4,995 and \$4,754, respectively  | 2,572                     | 2,632                       |
| Intangible assets, net  | 4,406                     | 4,211                       |
| Deferred income taxes   | 2,474                     | 2,643                       |
| Other non-current assets  | 54                        | 139                         |
| <b>Total Assets</b>   | <b>\$ 26,386</b>          | <b>\$ 30,678</b>            |
| <b>Liabilities and Shareholders' Equity</b>   |                           |                             |
| <b>Current Liabilities:</b>   |                           |                             |
| Accounts payable  | \$ 1,993                  | \$ 2,876                    |
| Employee compensation   | 1,290                     | 1,550                       |
| Deferred income   | 3,968                     | 4,007                       |
| Other current liabilities and accrued expenses  | 911                       | 948                         |
| Total current liabilities   | 8,162                     | 9,381                       |
| <b>Long-term liabilities:</b>   |                           |                             |
| Long-term deferred income and other   | 4,183                     | 4,374                       |
| <b>Total Liabilities</b>  | <b>12,345</b>             | <b>13,755</b>               |
| <b>Commitments and Contingencies</b>  |                           |                             |
| <b>Shareholders' Equity:</b>  |                           |                             |
| Common stock, \$0.10 par value, authorized 25,000,000 shares, 4,434,821 and 4,378,811 shares issued and 4,399,442 and 4,337,314 shares outstanding in 2017 and 2016, respectively | 440                       | 434                         |
| Undesignated shares, authorized 5,000,000 shares, No shares issued and outstanding  | —                         | —                           |
| Additional paid-in capital  | 22,224                    | 24,859                      |
| Accumulated deficit   | (8,395 )                  | (8,129 )                    |

|   |           |           |
|---|-----------|-----------|
| Accumulated other comprehensive loss              | (228 )    | (241 )    |
| <b>Total Shareholders' Equity</b>                 | 14,041    | 16,923    |
| <b>Total Liabilities and Shareholders' Equity</b> | \$ 26,386 | \$ 30,678 |

See accompanying notes to consolidated financial statements.

Table of Contents**MGC DIAGNOSTICS CORPORATION AND SUBSIDIARIES****Consolidated Statements of Comprehensive (Loss) Income**

(Unaudited in thousands, except per share data)

|  | Three Months ended<br>April 30, |          | Six Months ended<br>April 30, |           |
|--|---------------------------------|----------|-------------------------------|-----------|
|  | 2017                            | 2016     | 2017                          | 2016      |
| <b>Revenues</b>                                      |                                 |          |                               |           |
| Equipment, supplies and accessories revenues         | \$ 7,981                        | \$ 7,547 | \$ 14,873                     | \$ 14,948 |
| Service revenues                                     | 1,838                           | 1,884    | 3,686                         | 3,734     |
|  | 9,819                           | 9,431    | 18,559                        | 18,682    |
| <b>Cost of revenues</b>                              |                                 |          |                               |           |
| Cost of equipment, supplies and accessories revenues | 4,232                           | 3,672    | 7,957                         | 7,472     |
| Cost of service revenues                             | 623                             | 645      | 1,209                         | 1,219     |
|  | 4,855                           | 4,317    | 9,166                         | 8,691     |
| <b>Gross margin</b>                                  | 4,964                           | 5,114    | 9,393                         | 9,991     |
| <b>Operating expenses:</b>                           |                                 |          |                               |           |
| Selling and marketing                                | 2,443                           | 2,534    | 4,773                         | 5,035     |
| General and administrative                           | 1,712                           | 2,039    | 3,242                         | 3,451     |
| Research and development                             | 733                             | 678      | 1,323                         | 1,351     |
| Amortization of intangibles                          | 37                              | 60       | 79                            | 118       |
|  | 4,925                           | 5,311    | 9,417                         | 9,955     |
| <b>Operating income (loss)</b>                       | 39                              | (197 )   | (24 )                         | 36        |
| Interest expense, net                                | 2                               | 49       | 2                             | 115       |
| Foreign currency (gain) loss                         | (124 )                          | (416 )   | 52                            | (307 )    |
| <b>Income (loss) before taxes</b>                    | 161                             | 170      | (78 )                         | 228       |
| Provision for taxes                                  | 187                             | 125      | 188                           | 187       |
| <b>Net (loss) income</b>                             | (26 )                           | 45       | (266 )                        | 41        |
| <b>Other comprehensive (loss) income, net of tax</b> |                                 |          |                               |           |
| Effect of foreign currency translation adjustments   | (74 )                           | (6 )     | 13                            | (9 )      |
| <b>Comprehensive (loss) income</b>                   | \$ (100 )                       | \$ 39    | \$ (253 )                     | \$ 32     |
| <b>Net (loss) income per share:</b>                  |                                 |          |                               |           |
| Basic  | \$ (0.01 )                      | \$ 0.01  | \$ (0.06 )                    | \$ 0.01   |
| Diluted  | \$ (0.01 )                      | \$ 0.01  | \$ (0.06 )                    | \$ 0.01   |
| <b>Weighted average common shares outstanding:</b>   |                                 |          |                               |           |
| Basic  | 4,381                           | 4,306    | 4,361                         | 4,293     |
| Diluted  | 4,381                           | 4,319    | 4,361                         | 4,310     |
| <b>Dividends declared per share</b>                  | \$ —                            | \$ —     | \$ 0.70                       | \$ —      |

See accompanying notes to consolidated financial statements.





Table of Contents**MGC DIAGNOSTICS CORPORATION AND SUBSIDIARIES****Consolidated Statements of Cash Flows**

(Unaudited in thousands, except per share data)

|  | <b>Six Months ended April 30,</b> |                 |
|--|-----------------------------------|-----------------|
|  | <b>2017</b>                       | <b>2016</b>     |
| <b>Cash flows from operating activities:</b>   |                                   |                 |
| Net (loss) income  | \$ (266 )                         | \$ 41           |
| Adjustments to reconcile net (loss) income to net cash provided by operating activities: |                                   |                 |
| Depreciation   | 242                               | 212             |
| Amortization   | 145                               | 162             |
| Stock-based compensation   | 307                               | 348             |
| Deferred income taxes  | 166                               | 182             |
| Loss (gain) on foreign currency  | 40                                | (306 )          |
| Increase (decrease) in allowance for doubtful accounts                                   | 82                                | (16 )           |
| Decrease in inventory obsolescence reserve   | (18 )                             | (67 )           |
| Loss on disposal of equipment  | —                                 | 2               |
| Changes in operating assets and liabilities:   |                                   |                 |
| Accounts receivable  | 1,845                             | 898             |
| Inventories  | (33 )                             | (360 )          |
| Prepaid expenses and other current assets  | 65                                | 520             |
| Accounts payable   | (874 )                            | (96 )           |
| Employee compensation  | (258 )                            | (398 )          |
| Deferred income  | (209 )                            | 372             |
| Other current liabilities and accrued expenses   | (66 )                             | 316             |
| Net cash provided by operating activities  | 1,168                             | 1,810           |
| <b>Cash flows from investing activities:</b>   |                                   |                 |
| Purchases of property and equipment and intangible assets                                | (540 )                            | (454 )          |
| Net cash used in investing activities  | (540 )                            | (454 )          |
| <b>Cash flows from financing activities:</b>   |                                   |                 |
| Payment of long-term borrowing   | —                                 | (333 )          |
| Dividends paid   | (3,080 )                          | —               |
| Proceeds from issuance of common stock under employee stock purchase plan                | 30                                | 50              |
| Proceeds from the exercise of stock options  | 126                               | —               |
| Repurchase of common stock upon vesting of restricted stock awards                       | (5 )                              | (12 )           |
| Net cash used in financing activities  | (2,929 )                          | (295 )          |
| Effect of exchange rate changes on cash  | (7 )                              | (7 )            |
| <b>Net (decrease) increase in cash</b>   | <b>(2,308 )</b>                   | <b>1,054</b>    |
| <b>Cash at beginning of period</b>   | <b>7,265</b>                      | <b>6,553</b>    |
| <b>Cash at end of period</b>   | <b>\$ 4,957</b>                   | <b>\$ 7,607</b> |

Edgar Filing: MGC DIAGNOSTICS Corp - Form 10-Q

|   |        |        |
|---|--------|--------|
| Cash paid for taxes   | \$ 129 | \$ 132 |
| Cash paid for interest  | 2      | 72     |
| <b>Supplemental non-cash items:</b>                                   |        |        |
| Current and non-current liabilities issued for leasehold improvements | \$ —   | \$ 51  |
| Common stock issued for long-term liability                           | —      | 3      |
| Accrued dividends   | 7      | —      |

See accompanying notes to consolidated financial statements.

Table of Contents

**MGC Diagnostics Corporation and Subsidiaries**

**Notes to Consolidated Financial Statements**

(Unaudited)

**(1) Basis of Presentation and Description of Business**

MGC Diagnostics Corporation (the “Company”), through its Medical Graphics Corporation and Medisoft SA subsidiaries, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MGC Diagnostics and Medisoft brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications within cardiorespiratory healthcare.

The consolidated balance sheet as of April 30, 2017, the consolidated statements of comprehensive(loss) income for the three- and six-month periods ended April 30, 2017 and 2016, the consolidated statements of cash flows for the six-month periods ended April 30, 2017 and 2016 and the related information presented in these notes have been prepared by management in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X, without audit. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation of results have been included. The consolidated balance sheet at October 31, 2016 was derived from the audited consolidated financial statements as of that date. Operating results for the three- and six-month periods ended April 30, 2017 are not necessarily indicative of the results that may be expected for the year ending October 31, 2017. For further information, refer to the consolidated financial statements and notes thereto included in MGC Diagnostics Corporation’s Annual Report on Form 10-K for the year ended October 31, 2016.

Preparation of the consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities made in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Estimates include accounts receivable reserves, product warranty and inventory reserves, realizability of deferred tax assets and depreciable lives of property, equipment and intangible assets (including internal software development costs).

**(2) Summary of Significant Accounting Policies**

***Revenue Recognition***

The Company recognizes revenue when persuasive evidence of an arrangement exists, transfer of title has occurred or services have been rendered, the selling price is fixed or determinable and collectability is reasonably ensured. The Company's products are sold for cash or on unsecured credit terms requiring payment based on the shipment date. Credit terms can vary between customers due to many factors, but are generally, on average, 30 to 60 days. Revenue, net of discounts, is generally recognized upon shipment or delivery to customers in accordance with written sales terms. Standard sales terms do not include customer acceptance conditions, future credits, rebates, price protection or general rights of return. Although the terms of sales to both domestic customers and international distributors are identical, adherence to these terms is more pervasive with domestic customers than with international distributors. In instances when a customer order specifies final acceptance of the system, revenue recognition is deferred until all customer acceptance criteria have been met. Estimated warranty obligations are recorded upon shipment. In certain situations customer requested short-term bill-and-hold sale arrangements are accommodated and accounted for in accordance with authoritative literature. Sales and use taxes are reported on a net basis, excluding them from revenues and cost of revenues.

Service contract revenue is based on a stated contractual rate and is deferred and recognized ratably over the service period, which is typically from 1 to 5 years beginning after the expiration of the standard warranty. Deferred income associated with service contracts was \$7,346,000 and \$7,551,000 as of April 30, 2017 and October 31, 2016, respectively. Revenue from installation and training services provided to customers is deferred until the service has been performed or no further obligations to perform the service exist. The amount of deferred installation and training revenue was \$452,000 and \$533,000 as of April 30, 2017 and October 31, 2016, respectively.

## Table of Contents

When a sale involves multiple deliverables, such as equipment, installation services and training, the amount of the sale consideration is allocated to each respective element based on the relative selling price and revenue is recognized when revenue recognition criteria for each element are met. Consideration allocated to delivered equipment is equal to the total arrangement consideration less the selling price of installation and training. The selling price of installation and training services is based on specific objective evidence, including third-party invoices.

No customer accounted for more than 10% of revenue in either of the three- or six-month periods ended April 30, 2017 or 2016.

### *Advance Payments from Customers*

The Company typically does not receive advance payments from its customers in connection with the sale of its products. The Company occasionally enters into an arrangement under which a customer agrees to purchase a large quantity of product to be delivered over a period of time. Depending on the size of these arrangements, the Company may negotiate an advance payment from these customers. Advance payments from customers were \$227,000 and \$151,000 as of April 30, 2017 and October 31, 2016, respectively. Revenue recognition for customer orders that include advance payments is consistent with the Company's revenue recognition policy described above.

### *Internal Software Development Costs*

Internal software development costs consist primarily of internal salaries and consulting fees for developing software platforms for sale to or use by customers within equipment the Company sells. We capitalize costs related to the development of our software products because the Company will use these software products as an integral part of a product or process sold or leased. This software is primarily related to both our current Breeze Suite and our new next generation software platforms, including underlying support products. Capitalized software may also include other less significant projects supporting software for separate sale or for internal use.

We begin to capitalize costs related to software developed for new products and significant enhancements of existing products once we reach technological feasibility and we have completed all research and development for the components of the product. We amortize these costs on a straight-line basis over the estimated useful life of the related product, generally five years, but not more than ten years, commencing with the date the product becomes available for general release to our customers. We amortize costs for internal use software over the expected use periods of the software (See Note 5). The achievement of technological feasibility and the estimate of a product's economic life require management's judgment. Any changes in key assumptions, market conditions or other circumstances could result in an impairment of the capitalized software asset and a charge to our operating results.

### ***Income Taxes***

The Company uses the asset and liability method of accounting for income taxes in accordance with FASB ASC 740, *Income Taxes*. The Company recognizes deferred tax assets or liabilities for the expected future tax consequences of temporary differences between the book and tax basis of assets and liabilities. Each quarter, the Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income. The analysis to determine the amount of the valuation allowance is highly judgmental and requires weighing positive and negative evidence including historical and projected future taxable income and ongoing tax planning strategies. See Note 9 to the consolidated financial statements, "Income Taxes," for further discussion.

### ***Reclassification***

Certain prior year Medisoft service revenues and costs of service revenues amounts have been reclassified to conform with current year classifications. There was no impact, as a result of these reclassifications, on the consolidated balance sheet, the consolidated comprehensive (loss) income or the consolidated statement of cash flows as previously reported.

Table of Contents

*New Accounting Pronouncements*

Revenue from Contracts with Customers. In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance creating Accounting Standards Codification (“ASC”) Section 606, *Revenue from Contracts with Customers*. The new section will replace Section 605, *Revenue Recognition*, and creates modifications to various other revenue accounting standards for specialized transactions and industries. The section is intended to conform revenue accounting principles to a concurrently issued International Financial Reporting Standards to reconcile previously differing treatment between United States practices and those of the rest of the world and enhance disclosures related to disaggregated revenue information. In August 2015, the FASB deferred the effective date of the new guidance by one year, with the updated guidance now effective for annual reporting periods beginning after December 15, 2017, and interim periods within those fiscal years. The FASB has also issued ASU 2016-10 and ASU 2016-12, which are also related to ASC 606. The Company will adopt the new provisions of this accounting standard at the beginning of fiscal year 2019. The Company is currently evaluating the effect that this guidance will have on its consolidated financial statements.

In July 2015, FASB issued ASU 2015-11, *Inventory (Topic 330) Related to Simplifying the Measurement of Inventory*, which will apply to all inventory, except inventory that is measured using either last-in, first-out (LIFO) or the retail inventory method. Inventory measured using either first-in, first-out (FIFO) or average cost is covered by the new amendments. Inventory within the scope of the new guidance should be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is unchanged for inventory measured using LIFO or the retail inventory method. The amendments will take effect for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The new guidance should be applied prospectively, and earlier application is permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the effect that this guidance will have on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, *Leases*, to increase transparency and comparability among organizations by recognizing all lease transactions with an initial term longer than twelve months on the balance sheet as a lease liability and a right-of-use asset (as defined). ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with earlier application permitted, and requires a modified retrospective transition method upon adoption. The Company is currently evaluating the effect that ASU 2016-02 will have on its consolidated financial statements.

**(3) Shareholders' Equity**

The MGC Diagnostics Corporation 2007 Stock Incentive Plan (the “2007 Plan”) provides that incentive stock options and nonqualified stock options to purchase shares of common stock may be granted at prices determined by the Human Capital Committee of the Company's Board of Directors, except that the purchase price of incentive stock options may not be less than the fair market value of the stock at the date of grant. Options under the 2007 Plan are subject to vesting schedules established on the date of grant. In addition, the 2007 Plan allows the granting of restricted stock awards, stock appreciation rights and performance stock.



Total stock-based compensation expense included in the Company's statements of comprehensive income was \$133,000 and \$204,000 for the three-month periods ended April 30, 2017 and 2016, respectively, and was \$307,000 and \$348,000 for the six-month periods ended April 30, 2017 and 2016, respectively.

***Stock Options***

A summary of the Company's stock option activity for the six months ended April 30, 2017 and 2016 is presented in the following table:

|                                    | For the Six Months ended<br>April 30, 2017 |  | April 30, 2016 |  |
|------------------------------------|--|--|----------------|--|
|                                    | Shares                                     | Weighted<br>Average<br>Exercise<br>Price | Shares         | Weighted<br>Average<br>Exercise<br>Price |
| Outstanding at beginning of period | 371,733                                    | \$ 6.64                                  | 177,900        | \$ 6.48                                  |
| Granted                            | 34,000                                     | 8.20                                     | 68,638         | 6.55                                     |
| Exercised                          | (20,999 )                                  | 6.02                                     | —              | —  |
| Expired or cancelled               | (75,000 )                                  | 6.66                                     | (13,305 )      | 6.62                                     |
| Outstanding at end of period       | 309,734                                    | \$ 6.85                                  | 233,233        | \$ 6.49                                  |

Table of Contents

The following table summarizes information concerning stock options outstanding as of April 30, 2017:

| Exercise Prices | Number<br>Outstanding | Weighted<br>Average<br>Remaining<br>Contractual<br>Life | Number<br>Subject to<br>Exercise |
|-----------------|-----------------------|---|----------------------------------|
| \$5.65          | 10,000                | 5.95  | 3,334                            |
| 6.07            | 116,667               | 5.08  | 50,001                           |
| 6.63            | 10,001                | 5.61  | 2,664                            |
| 6.76            | 4,900                 | 5.54  | 4,900                            |
| 6.77            | 33,333                | 1.76  | 33,333                           |
| 7.05            | 80,000                | 6.36  | —                                |
| 7.52            | 20,000                | 6.63  | —                                |
| 8.40            | 4,000                 | 6.93  | —                                |
| 9.12            | 20,833                | 4.09  | 14,999                           |
| 9.48            | 10,000                | 6.76  | 10,000                           |
| Total           | 309,734               | 5.22  | 119,231                          |

The total intrinsic values for outstanding options and exercisable options as of April 30, 2017 were \$539,000 and \$204,000, respectively, calculated using the closing stock price at the end of the second quarter less the option price of in-the-money options. The Company issues new shares when stock options are exercised. Unrecognized compensation expense related to outstanding stock options as of April 30, 2017 was \$438,000 and is expected to be recognized over a weighted average period of 1.66 years.

**Valuation Assumptions**

The Company uses the Black-Scholes option-pricing model (“Black-Scholes model”) to determine the fair value of stock options as of the grant date. In determining the fair value of stock options under the Black-Scholes model, management must make assumptions regarding projected employee stock option exercise behaviors, risk-free interest rates, volatility of the Company’s stock price and expected dividends. The expense recognized for options granted under the 2007 Plan is equal to the fair value of stock options as of the grant date. The following table provides the weighted average fair value of options granted to employees and the related assumptions used in the Black-Scholes model for stock option grants made during the six months ended April 30, 2017:

|  | Options Granted<br>April 3, 2017 | Options Granted<br>February 2, 2017 | Options Granted<br>December 15, 2016 |
|--|----------------------------------|-------------------------------------|--------------------------------------|
| Weighted average fair value of options granted | \$ 3.91                          | \$ 4.37                             | \$ 3.48                              |
| Assumptions used:                              |                                  |                                     |                                      |
| Expected life (years)                          | 7.00                             | 7.00                                | 7.00                                 |
| Risk-free interest rate                        | 1.90 %                           | 1.92 %                              | 1.90 %                               |

|                |       |   |       |   |       |   |
|----------------|-------|---|-------|---|-------|---|
| Volatility     | 42.65 | % | 42.06 | % | 42.45 | % |
| Dividend Yield | —     | % | —     | % | —     | % |

***Restricted Stock Awards***

Restricted stock awards are awards of common stock that are subject to restrictions on transfer and to a risk of forfeiture if the holder leaves the Company before the restrictions lapse. The holder of a restricted stock award is generally entitled at all times on and after the date of issuance of the restricted shares to exercise the rights of a shareholder of the Company, including the right to vote the shares. The value of stock awards that vest over time is established by the market price on the date of its grant. A summary of the Company's restricted stock activity for the six months ended April 30, 2017 and 2016 is presented in the following table:

Table of Contents

|                                 | For the Six Months ended<br>April 30, 2017 |   | April 30, 2016 |   |
|---------------------------------|--|---|----------------|---|
|                                 | Shares                                     | Weighted<br>Average<br>Grant Date<br>Fair Value | Shares         | Weighted<br>Average<br>Grant Date<br>Fair Value |
| Unvested at beginning of period | 41,497                                     | \$ 6.59   | 49,993         | \$ 7.61   |
| Granted                         | 27,546                                     | 8.74  | 31,998         | 6.00  |
| Vested                          | (33,664 )                                  | 6.15  | (31,594 )      | 6.98  |
| Unvested at end of period       | 35,379                                     | \$ 8.68   | 50,397         | \$ 7.27   |

Unrecognized compensation expense related to outstanding restricted stock awards to employees and directors as of April 30, 2017 was \$231,000 and is expected to be recognized over a weighted average period of 1.30 years.

***Director Stock Awards in Lieu of Cash Retainer Fees***

The Company has a program that allows non-employee Board members to elect and receive shares from the 2007 Plan in lieu of some or all of their quarterly cash retainer fees. During the three months ended April 30, 2017 and 2016, the Company issued 1,282 and 1,639 shares, respectively, and during the six months ended April 30, 2017 and 2016, the Company issued 2,771 and 3,342 shares, respectively, under this program. The expense was recognized at the time of share issuance and totaled \$11,000 in each of the three-month periods ended April 30, 2017 and 2016, and \$22,000 in each of the six-month periods ended April 30, 2017 and 2016.

***Employee Stock Purchase Plan***

The MGC Diagnostics Corporation 2003 Employee Stock Purchase Plan, as amended (“Purchase Plan”), allows participating employees to purchase up to 200,000 shares of the Company’s common stock at a discount through payroll deductions. The Purchase Plan is available to all employees subject to eligibility requirements. Under the Purchase Plan, participating employees may purchase the Company’s common stock on a voluntary after-tax basis at a price that is the lower of 85% of the fair market value of one share of common stock at the beginning or end of each stock purchase phase. The Purchase Plan is carried out in six-month phases, with phases beginning on January 1 and July 1 of each calendar year. For the phase that ended on December 31, 2016, employees purchased 5,343 shares at a price of \$5.54 per share. As of April 30, 2017, the Company has withheld approximately \$21,000 from employees participating in the phase that began on January 1, 2017. As of April 30, 2017, 44,010 shares of common stock were available for future purchase under the Purchase Plan.

The following table presents the classification of pre-tax stock-based compensation expense recognized in the consolidated statements of comprehensive (loss) income for the three months and six months ended April 30, 2017 and 2016:

| (In thousands)                   | Three Months ended April 30, |        | Six Months ended April 30, |        |
|----------------------------------|------------------------------|--------|----------------------------|--------|
|                                  | 2017                         | 2016   | 2017                       | 2016   |
| Cost of revenues                 | \$ 18                        | \$ 1   | \$ 19                      | \$ 2   |
| Selling and marketing            | 55                           | 29     | 93                         | 58     |
| General and administrative       | 53                           | 173    | 186                        | 285    |
| Research and development         | 7                            | 1      | 9                          | 3      |
| Stock-based compensation expense | \$ 133                       | \$ 204 | \$ 307                     | \$ 348 |

### *Tax Impact of Stock-Based Compensation*

The Company reports the benefit of tax deductions in excess of recognized stock-based compensation expense on the consolidated statements of cash flows as operating cash flows. For the six months ended April 30, 2017 and 2016, there were No excess tax benefits recognized.

### *Dividend*

On January 25, 2017, the Company declared a special cash dividend of \$0.70 per share on its outstanding common stock to all shareholders of record as of February 10, 2017. The dividend was paid on February 24, 2017.

Table of Contents**(4) Inventories**

Inventories consisted of the following as of April 30, 2017 and October 31, 2016:

| (In thousands)      | 2017     | 2016     |
|---------------------|----------|----------|
| Current Assets:     |          |          |
| Raw materials       | \$ 2,142 | \$ 2,072 |
| Work-in-process     | 965      | 827      |
| Finished goods      | 1,927    | 2,017    |
|                     | 5,034    | 4,916    |
| Non-current Assets: |          |          |
| Finished goods      | 46       | 115      |
|                     | \$ 5,080 | \$ 5,031 |

**(5) Intangible Assets**

Intangible assets consisted of the following as of April 30, 2017 and October 31, 2016:

| (In thousands)                         | 2017     | 2016     |
|--|----------|----------|
| Intangible assets:                     |          |          |
| Developed technology                   | \$ 7,802 | \$ 7,802 |
| Customer and distributor relationships | 371      | 373      |
| Trademarks and trade names             | 252      | 254      |
| Software                               | 891      | 849      |
| Capitalized software in progress       | 3,140    | 2,841    |
|  | 12,456   | 12,119   |
| Less: accumulated amortization         | (8,050 ) | (7,908 ) |
|  | \$ 4,406 | \$ 4,211 |

The Company amortizes the intangible assets related to developed technology, patents and trademarks using the straight-line method over the estimated useful lives of the assets, which range from 5 to 10 years. Total amortization expense was \$35,000 and \$92,000 for the three months ended April 30, 2017 and 2016, respectively and \$76,000 and \$162,000 for the six months ended April 30, 2017 and 2016, respectively. Of the total, amortization expenses of \$32,000 and \$25,000 related to software costs are included in the cost of equipment, supplies and accessories revenues for the three-month periods ended April 30, 2017 and 2016, respectively, and \$66,000 and \$37,000 for the six-month periods ended April 30, 2017 and 2016, respectively. The Company estimates it will incur the following amortization expense in the balance of fiscal 2017 and in future fiscal years based on the intangible assets the Company expects to have placed in service at the end of fiscal 2017:

| <b>(In thousands)</b>              | <b>Amortization</b> |       |
|------------------------------------|---------------------|-------|
| Six months ending October 31, 2017 | \$                  | 226   |
| 2018                               |                     | 575   |
| 2019                               |                     | 533   |
| 2020                               |                     | 510   |
| 2021                               |                     | 445   |
| 2022                               |                     | 374   |
| Thereafter                         |                     | 1,411 |
|                                    | \$                  | 4,074 |

This table does not include estimated amortization expense of \$86,000 for patents included in “Developed technology,” or of \$246,000 for capitalized software costs the Company expects to place into service after the current fiscal year. The Company capitalized software development costs of \$181,000 and \$196,000 during the three-month periods ended April 31, 2017 and 2016, respectively, and \$341,000 and \$366,000 during the six-month periods ended April 30, 2017 and 2016, respectively. Upon completion of these development projects, the Company expects to amortize the capitalized software costs over a ten year period.

Table of Contents**(6) Warranty Reserve**

Sales of the Company's equipment are subject to a warranty obligation. Equipment warranties typically extend for a period of twelve months from the date of installation. Standard warranty terms are included in customer contracts. Under the terms of these warranties, the Company is obligated to repair or replace any components or assemblies that it deems defective in workmanship or materials. The Company reserves the right to reject warranty claims if it determines that failure is due to normal wear, customer modifications, improper maintenance or misuse. The Company maintains a warranty reserve that reflects the estimated expenses it will incur to honor the warranties on its products. The Company adjusts the warranty reserve based on the number and type of equipment subject to warranty and the remaining months of warranty coverage. The warranty reserve adjustment reflects the Company's historical warranty experience based on the type of equipment.

Warranty provisions and claims for the six months ended April 30, 2017 and 2016 were as follows:

| (In thousands)                         | 2017   | 2016   |
|--|--------|--------|
| Balance, beginning of period           | \$ 151 | \$ 147 |
| Warranty provision based on units sold | 104    | 137    |
| Periodic reserve adjustments           | 5      | (50 )  |
| Warranty claims                        | (138 ) | (123 ) |
| Balance, end of period                 | \$ 122 | \$ 111 |

**(7) Financing Arrangements**

On July 24, 2014, the Company entered into a credit agreement with BMO Harris Bank NA. The Agreement, as amended, included a \$4.0 million term loan and a \$250,000 revolving credit facility. The term loan, which bore interest at a floating rate, was payable in equal monthly principal installments of \$66,667 over a five year period commencing August 31, 2014 and was evidenced by a term note. The Company borrowed the \$4.0 million under the term loan on July 24, 2014 and used these proceeds in connection with its August 1, 2014 acquisition of Medisoft SA. On June 14, 2016, the Company paid off the remaining balance of the term loan and terminated the revolving credit facility.

**(8) Net Income (Loss) per Share**

Basic income (loss) per share is computed by dividing net income (loss) by the weighted average shares outstanding during the reporting period. Diluted income per share is computed similarly to basic income (loss) per share except



that the weighted average shares outstanding are increased to include additional shares issuable from the assumed exercise of warrants and stock options, if dilutive, as well as the dilutive effects of any unvested restricted share awards. Diluted loss per share does not include any of these dilutive effects in its calculation. The number of additional shares is calculated by assuming that outstanding warrants and stock options are exercised, outstanding restricted share grants vest and that the cash proceeds from the exercise together with the assumed employment value represented by the unamortized stock-based compensation were used to reacquire shares of common stock at the average market price during the reporting period.

The Company had unexpired options and warrants for the purchase of its common stock and unvested restricted awards as of April 30, 2017 and 2016 of 513,455 and 451,972 shares, respectively.

Shares used in the net income (loss) per share computations are as follows:

| (In thousands)  | Three Months ended April 30, |       | Six Months ended April 30, |       |
|---|------------------------------|-------|----------------------------|-------|
|   | 2017                         | 2016  | 2017                       | 2016  |
| Weighted average common shares outstanding - basic                        | 4,381                        | 4,306 | 4,361                      | 4,293 |
| Dilutive effect of stock options, warrants and unvested restricted shares | —                            | 13    | —                          | 17    |
| Weighted average common shares outstanding - diluted                      | 4,381                        | 4,319 | 4,361                      | 4,310 |

Anti-dilutive shares excluded from the calculation for each of the three- and six-month periods ended April 30, 2016 totaled 432,576 and 432,576, respectively. As a result of the net loss for the three- and six-month periods ended April 30, 2017, all outstanding warrants, stock options and unvested restricted stock shares were considered anti-dilutive and, therefore, were excluded from diluted loss per share for each period.

Table of Contents

**(9) Income Taxes**

The Company has recorded a provision for income taxes of \$187,000 and \$125,000 for the three months ended April 30, 2017 and 2016, respectively and \$188,000 and \$187,000 for the six months ended April 30, 2017 and 2016, respectively. The Company records its interim provision for income taxes based on its estimated worldwide annual effective rate for the year, excluding MGC Diagnostics Belgium S.P.R.L. net losses of \$140,000 and \$234,000 for the three- and six-month periods ended April 30, 2017 and \$104,000 and \$192,000) for the three- and six-month periods ended April 30, 2016, respectively, for which no tax benefit can be recognized due to expected future losses and the resulting valuation allowance related to these losses. As such, the \$188,000 fiscal 2017 year to date tax expense compared to the world wide consolidated pre-tax income of \$157,000 (which excludes the Medisot Belgium S.P.R.L. loss) results in an effective rate of approximately 119.8%.

For the six months ended April 30, 2017, the Company recorded a domestic income tax expense of \$135,000 based on an estimated U.S. annual effective tax rate of 45.2%. The differences from the federal statutory rate result from the effects of anticipated federal alternative minimum tax (AMT) whose credit cannot be offset due to the partial valuation allowance, state taxes expected to be paid and permanent differences whose effects are to increase the effective rate, including non-deductible meals and entertainment expenses, stock-based compensation expenses related to incentive stock options and restricted stock awards and expense related to reserves for uncertain tax positions. For the six months ended April 30, 2017, the foreign tax expense of \$53,000 is primarily from the increase in the valuation allowance against the deferred tax assets for Medisoft Belgium.

As of April 30, 2017, the Company had a reserve for uncertain tax positions of \$95,000 compared to the October 31, 2016 balance of \$92,000. If recognized, approximately \$61,000 of these benefits would lower the effective tax rate. The remaining \$34,000, if recognized, would result in a deferred tax asset subject to a valuation allowance and therefore would not affect the effective rate.

Estimated interest and penalties related to potential underpayment of income taxes are classified as a component of tax expense in the consolidated statements of comprehensive (loss) income. The Company does not expect the amount of reserves for uncertain tax positions to change significantly in the next twelve months. Similarly, the Company does not anticipate that the total reserve for uncertain tax positions will significantly change due to the settlement of audits and the expiration of statutes of limitations within the next twelve months.

The Company files a consolidated federal income tax return in the United States federal jurisdiction and files various combined and separate tax returns in several state and local jurisdictions. For United States federal tax, the Company is no longer subject to examinations by the authorities for fiscal years ending prior to November 1, 1998. The expiration dates of the statute of limitations related to the various state income tax returns vary by state. There is no statute of limitations for assessments related to jurisdictions where the Company may have a nexus but has chosen not to file an income tax return.

The Company has federal net operating loss (“NOL”) and general business tax credit carry forwards; however, the utilization of some of these tax loss and tax credit carry forwards is limited under Internal Revenue Code (“IRC”) §382 and §383, respectively, as a result of an IRS-deemed change in ownership that occurred in the fourth quarter of fiscal 2006. The Company’s estimated domestic NOL carry forwards of \$6.5 million that are not limited as of October 31, 2016 include \$2.8 million of income tax deductions in excess of previously recorded tax benefits. The tax benefit of these excess deductions was added to deferred tax assets as of October 31, 2016 as a result of the adoption of ASU 2016-09 retroactively to November 1, 2015; however the additional benefit was offset by an equivalent increase to the valuation allowance for domestic net deferred tax assets. These loss carry forwards will expire in years 2018 through 2032. Additionally, the Company has general business credit carry forwards of \$461,000 that will expire in 2033. Use of this general business credit carry forward is not limited because it was generated after the change in ownership. The Company also has \$266,000 of alternative minimum tax credit carry forwards that do not have expiration dates. The alternative minimum tax credit carry forwards are limited by IRC §383, but their ultimate use is not affected since these do not expire. In addition, as of October 31, 2016, the Company has foreign NOL carry forwards of approximately \$4.8 million. Foreign NOL expiration varies by country; however, a substantial portion of the foreign NOLs are in Belgium, and do not expire. As of October 31, 2016, the Company had a remaining valuation allowances for domestic and international entities of approximately \$1,951,000 and \$772,000, respectively.

Table of Contents**(10) Segment Reporting**

The Company operates in a single industry segment, the manufacture and sale of cardiorespiratory diagnostic products. The Company sells its products into many countries throughout the world. Net sales and long-lived assets by geographic area are shown in the following tables.

| (In thousands)                        | Three Months ended April 30, |          | Six Months ended April 30, |           |
|---------------------------------------|------------------------------|----------|----------------------------|-----------|
|                                       | 2017                         | 2016     | 2017                       | 2016      |
| Revenues from unaffiliated customers: |                              |          |                            |           |
| United States                         | \$ 7,134                     | \$ 7,119 | \$ 13,415                  | \$ 14,119 |
| Americas                              | 490                          | 222      | 936                        | 403       |
| Europe, Middle East, Africa           | 1,785                        | 1,574    | 3,342                      | 3,146     |
| Asia Pacific                          | 410                          | 516      | 866                        | 1,014     |
|                                       | \$ 9,819                     | \$ 9,431 | \$ 18,559                  | \$ 18,682 |

|                    | April 30, 2017 | October 31, 2016 |
|--------------------|----------------|------------------|
| Long-lived assets: |                |                  |
| United States      | \$ 6,918       | \$ 6,829         |
| Europe             | 2,588          | 2,796            |
|                    | \$ 9,506       | \$ 9,625         |

**(11) Litigation**

The Company is also subject to certain claims and lawsuits that have been filed in the ordinary course of business. From time to time, the Company initiates lawsuits against others to enforce patents or to seek collection of debts in the ordinary course of business. The Company is not subject to any significant litigation, except as set forth below.

**MGC Diagnostics Corporation v. Mr. Guy Martinot and Dr. Jean-Benoît Martinot**

In November 2015, the Company commenced litigation in the French-speaking courts of Brussels, Belgium against the selling shareholders of Medisoft for violations of representations and warranties in the stock purchase agreement dated as of July 10, 2014 under which the Company purchased Medisoft. The Company alleged that these violations resulted in Company damages of approximately €985,400 (\$1,084,000). In May 2015, the Company received payment of €406,700 (\$447,000) with respect to these alleged violations pursuant to a bank guaranteed contractual escrow fund and has reflected that payment on its books and records. On May 30, 2016, the defendant selling shareholders filed an answer and asserted a counterclaim against the Company seeking to recover the €406,700 that was paid to the Company in May 2015 and legal costs. The Company continues to believe the Medisoft selling shareholders are liable

to it for violations of representations and warranties in the stock purchase agreement and intends to continue to pursue this matter. The Company has not accrued any losses related to the litigation or accrued any related legal costs it has not yet incurred. The Company currently expects that this litigation process may continue until the fall of 2018.

### **Neurovirtual USA, Inc. v. MGC Diagnostics Corporation**

The Company was also involved in litigation with Neurovirtual USA that it settled in June 2016. In that settlement the Company made a one-time cash payment of \$650,000 to Neurovirtual and each party agreed to dismiss with prejudice the lawsuit and all claims against the other party. As part of the settlement, the Company has retained Neurovirtual sleep diagnostics inventory that it purchased and Neurovirtual agreed to support this inventory pursuant to the distribution agreement. The Company has no continuing obligation to purchase additional Neurovirtual diagnostics products.

The Company recorded a loss of \$650,000, which was included in general and administrative expense for the quarter ended April 30, 2016. For the quarter ended October 31, 2016, the Company recorded an impairment loss of \$354,000 with respect to a portion of its sleep diagnostic inventory, which resulted from its ongoing analysis of projected unit sales in future periods. The Company continues to carry inventory and other noncurrent assets valued at \$68,000 and \$46,000, respectively, as of April 30, 2017.

### **(12) Subsequent Event**

In May 2016, the Company entered into the Fifth Addendum to its lease for its Saint Paul manufacturing and office facility, extending its lease commitment by one year to December 31, 2018. Monthly rental payments total to an annual commitment of \$338,000 in the extension period. The agreement includes a Company right to extend the lease through December 31, 2019.

Table of Contents**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operation.****Overview**

The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, designs and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MGC Diagnostics and Medisoft brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications within cardiorespiratory healthcare. Revenues consist of equipment, supplies and accessories sales as well as service revenues. Equipment, supplies and accessories sales reflect sales of non-invasive cardiorespiratory diagnostic equipment and aftermarket sales of peripherals and supplies. Service revenues consist of revenues from extended service contracts and non-warranty service visits.

Total revenues for the 2017 second quarter increased by 4.1% to \$9.8 million compared to \$9.4 million in the same period in 2016. Second quarter operating expenses were \$4.9 million compared to \$5.3 million in the prior year quarter. Net loss for the three months ended April 30, 2017 was \$(26,000), or \$(0.01) per diluted share, compared to net income of \$45,000, or \$0.01 per diluted share, for the same period in 2016. Net (loss) income for the three months ended April 30, 2017 and 2016 included foreign exchange gains of \$124,000 and \$416,000, respectively, which resulted from the value fluctuation of the Euro in relation to the U.S. dollar.

**Results of Operations**

The following table contains selected information from our consolidated statements of comprehensive (loss) income, expressed as a percentage of revenue:

|                                     | Three Months ended April 30, |   |       |   | Six months ended April 30, |   |       |   |
|-------------------------------------|------------------------------|---|-------|---|----------------------------|---|-------|---|
|                                     | 2017                         |   | 2016  |   | 2017                       |   | 2016  |   |
| Revenues                            | 100.0                        | % | 100.0 | % | 100.0                      | % | 100.0 | % |
| Cost of revenues                    | 49.4                         |   | 45.8  |   | 49.4                       |   | 46.5  |   |
| Gross margin                        | 50.6                         |   | 54.2  |   | 50.6                       |   | 53.5  |   |
| Operating Expenses                  |                              |   |       |   |                            |   |       |   |
| Selling and marketing expenses      | 24.9                         |   | 26.9  |   | 25.7                       |   | 27.0  |   |
| General and administrative expenses | 17.4                         |   | 21.6  |   | 17.5                       |   | 18.5  |   |
| Research and development expenses   | 7.5                          |   | 7.2   |   | 7.1                        |   | 7.2   |   |
| Amortization of intangibles         | 0.4                          |   | 0.6   |   | 0.4                        |   | 0.6   |   |
| Total operating expenses            | 50.2                         |   | 56.3  |   | 50.7                       |   | 53.3  |   |
| Operating income (loss)             | 0.4                          |   | (2.1) | ) | (0.1)                      | ) | 0.2   |   |

|                              |         |        |         |        |
|------------------------------|---------|--------|---------|--------|
| Interest expense, net        | —       | 0.5    | —       | 0.6    |
| Foreign currency (gain) loss | (1.2 )  | (4.4 ) | 0.3     | (1.6 ) |
| Provision for taxes          | 1.9     | 1.3    | 1.0     | 1.0    |
| Net (loss) income            | (0.3 )% | 0.5 %  | (1.4 )% | 0.2 %  |

### Seasonality

The Company experiences some seasonality in its revenues, with the first and fourth quarter of its fiscal year historically being its lowest and highest revenue quarters, respectively. The Company experiences additional variability in each quarter due to a number of factors, including customer budget cycles, product introductions, Company sales incentive programs, general economic conditions and the timing of customer orders.

Table of Contents

**Quarterly Comparison of Operations**

The following paragraphs discuss the Company's performance for the three months ended April 30, 2017 and 2016.

**Revenues**

Total revenues for the three months ended April 30, 2017 increased 4.1% compared to the same period in fiscal 2016. Equipment, supplies and accessories revenue increased 5.7% for the fiscal second quarter, with domestic revenue increasing by 0.4% to \$5.4 million and international revenue increasing by 19.2% to \$2.6 million due to stronger demand in the Latin America, Canada and Europe/Middle East markets.

Service revenue was \$1.8 million and \$1.9 million for the 2017 and 2016 second quarters, respectively.

The Attachment Rate, which reflects the percentage of Extended Service Contracts that were sold during customer equipment purchases, was 20% and 34% for the fiscal 2017 and 2016 **second** quarters, respectively. Current and long-term deferred revenue at the end of the fiscal 2017 **second** quarter increased 13.8% to \$8.0 million, compared to \$7.1 million at the end of last year's second quarter. This increase is due to an increase in sales of long-term service agreements.

Revenues from competitive conversions were \$1.0 million in the fiscal 2017 **second** quarter compared to \$1.3 million in the same quarter of the prior year.

Sales backlog at the end of the **second** quarter totaled \$2.0 million, compared to a backlog of \$1.9 million at the end of last year's **second** quarter. Of the total backlog for the 2017 **second** quarter, our domestic business contributed \$1.7 million and our international business contributed \$0.3 million.

**Gross Margin**



Gross margin of 50.6% in the fiscal **second** quarter includes gross margin for domestic revenues of 54.1% and international gross margin of 41.0% compared to gross margin of 54.2% for last year's **second** quarter, with domestic gross margin of 57.2% and international gross margin of 45.0%. The decline in gross margins for both domestic and international business is due primarily to the unfavorable sales mix of customers and products during the period. Total gross margins were lower than prior year as a result of strong growth in our international revenues (which are sold through distribution partners, thus carrying a lower gross margin) compared to relatively flat domestic revenue. Gross margin for equipment, supplies and accessories was 47.0% for the quarter (50.0% for domestic and 40.6% for international), compared to 51.3% in the prior year's quarter (54.1% for domestic and 44.7% for international). Service gross margin was 66.1% for the quarter (67.0% for domestic and 50.0% for international), compared to 65.8% for the prior year's quarter (67.0% for domestic and 50.0% for international).

### **Selling and Marketing**

Sales and marketing expenses were \$2.4 million, or 24.9% of revenue in the fiscal 2017 second quarter compared to \$2.5 million, or 26.9%, of revenue in the fiscal 2016 **second** quarter. This decrease is primarily due to decreases of \$109,000 in **telemarketing costs**, \$69,000 in Medisoft costs and \$29,000 of consulting costs, offset in part by an increase of \$30,000 of variable selling costs and \$79,000 of promotions and demonstration expenses.

### **General and Administrative**

General and administrative expenses totaled \$1.7 million, or 17.4% of revenue, compared to \$2.0 million, or 21.6%, of revenue in the comparable quarter last year. This resulted primarily from a decrease in litigation settlement costs of \$670,000 related to a settlement agreement completed in June 2016 and \$71,000 of non-employee stock based compensation, partially offset by increases of \$119,000 in personnel headcount and incentive costs, \$97,000 in Medisoft expenses, \$86,000 in strategic consulting fees, \$60,000 for bad debt reserves and \$35,000 in travel costs.

Table of Contents

**Research and Development**

Research and development expenses were \$733,000, or 7.5% of revenue in the fiscal second quarter, up from \$678,000, or 7.2%, of revenue in last year's second quarter. This increase is primarily due to \$103,000 in consulting costs, offset in part by \$37,000 of lower Medical Graphics personnel costs. Medical Graphics remains dedicated to developing new products and improving its existing products.

**Amortization of Intangibles**

Amortization of acquired Medisoft intangibles was \$35,000 and \$50,000 for the three months ended April 30, 2017 and 2016, respectively. Amortization of patent costs was \$2,000 and \$10,000 for the three months ended April 30, 2017 and 2016, respectively.

The amortization of software development assets was \$32,000 and \$25,000 for the three months ended April 30, 2017 and 2016, respectively, and is included in the cost of equipment revenues due to the direct relationship to equipment units sold. The Company expects the level of future amortization expense related to capitalized software development costs to increase as the Company releases its current projects under development.

**Provision for Taxes**

The Company has recorded a provision for income taxes of \$187,000 and \$125,000 for the three months ended April 30, 2017 and 2016, respectively. The Company records its interim provision for income taxes based on its estimated worldwide annual effective rate for the year excluding MGC Diagnostics Belgium S.P.R.L. net losses of \$140,000 and \$104,000 for the three-month periods ended April 30, 2017 and 2016, respectively, for which no tax benefit can be recognized due to future expected losses and resulting valuation allowance related to these losses. As such, the \$187,000 tax expense for the fiscal 2017 second quarter compared to the world wide consolidated pre-tax income of \$301,000 (which excludes the Medisoft Belgium S.P.R.L. loss) results in an effective rate of approximately 62%. The \$125,000 tax expense for the fiscal 2016 tax expense resulted in an effective rate for the quarter of approximately 73.5%. The provisions for income taxes for fiscal 2017 and 2016 include federal alternative minimum tax expense, state and foreign income tax expense and expense related to increased reserves for uncertain tax positions expected.

The \$187,000 fiscal 2016 year to date expense compared to the world wide consolidated pre-tax income of \$228,000 (which includes the Medisoft Belgium S.P.R.L. loss) results in an effective rate of 82%.

### **Interest Expense**

The interest expense decrease is due to the June 2016 payoff of long-term debt and the reduction of non-bank related foreign charges.

### **Foreign Exchange**

During the three months ended April 30, 2017 and 2016, changes in the value of the Euro expressed in U.S. dollars resulted in \$124,000 and \$416,000 of foreign currency gains, primarily due to the changes in value of the \$7.5 million intercompany Euro-denominated note used to partially finance the acquisition of Medisoft. In addition, pertaining to the net asset position for assets and liabilities of Medisoft, we also incurred a non-cash foreign currency translation loss of \$74,000, which is included in the consolidated balance sheets as accumulated other comprehensive income and in the consolidated statements of comprehensive (loss) income as other comprehensive income.

### **Six Month Comparison of Operations**

The following paragraphs discuss the Company's performance for the six months ended April 30, 2017 and 2016.

### **Revenues**

Total revenues for the six months ended April 30, 2017 decreased 0.7% compared to the same period in fiscal 2016. For the six months ended April 30, 2017, domestic revenue decreased by 4.9% to \$13.4 million and international revenue increased 12.4% to \$5.1 million.

Revenues from competitive conversions were \$1.6 million in the fiscal 2017 six-month period compared to \$2.5 million in the same period of the prior year. The Attachment Rate, which reflects the percentage of Extended Service Contracts that were sold during customer equipment purchases, was 24% for the first six months compared to the fiscal 2016 overall average rate of 31%.

International equipment, supplies and accessories revenues increased 14.6% to \$4.9 million, compared to \$4.3 million for the fiscal 2016 first half, due to stronger demand in the Latin America, Canada, and Europe/Middle East regions.

## Table of Contents

### **Gross Margin**

Gross margin of 50.6% in the six months ended April 30, 2017 includes gross margin for domestic sales of 54.0% and international sales of 41.6%. The decline in gross margins is due primarily to an unfavorable sales mix of customers and products during the period. The lower international gross margin is due primarily to reliance on an international sales model under which product gross margin is shared with distribution partners, who operate in more price sensitive markets. Gross margin for equipment, supplies and accessories was 46.5% for the first half (49.1% for domestic and 41.3% for international), compared to 50.0% in the prior year (52.8% for domestic and 43.1% for international). Gross margin for services was 67.2% for the fiscal 2017 first half, compared to 67.4% for the prior year comparable period. The Company's historical gross margins have ranged around 52% to 53%. We anticipate gross margins greater than 50% but not greater than 52% for overall fiscal 2017.

### **Selling and Marketing**

Sales and marketing expenses were \$4.8 million, or 25.7% of revenue for the first half of fiscal 2017 compared to \$5.0 million, or 27.0% of revenue in the fiscal 2016 first half. This decrease included \$83,000 of telemarketing expenses, \$53,000 of Medisoft expenses, \$47,000 of convention costs, \$45,000 of variable selling costs, \$42,000 of personnel and incentive expenses and \$31,000 of consulting expenses, offset in part by increased dues and customer promotion expenses of \$53,000.

### **General and Administrative**

General and administrative expenses totaled \$3.2 million, or 17.5% of revenue in the fiscal 2017 first half year, compared to \$3.5 million, or 18.5% of revenue for the fiscal 2016 first half year. This decrease is primarily due to reduced litigation settlement expenses of \$670,000 and non-employee compensation of \$82,000, offset by \$206,000 of increased employee payroll and incentive costs, \$130,000 of legal, investor relations, audit and consulting costs, \$103,000 of write-offs of doubtful accounts receivable and \$38,000 of travel expenses.

### **Research and Development**

Research and development expenses were \$1.3 million, or 7.1% of revenue in the 2017 fiscal first half, down from \$1.4 million, or 7.2% of revenue, in last year's comparable period. This decrease is primarily due to \$53,000 of net savings on research and development costs and \$112,000 of personal and incentive expenses, offset by \$120,000 of investment in a clinical research study in support of expanded indications for use of the Forced Oscillation Technique

equipment. Internal software development costs capitalized totaled \$341,000 and \$366,000 in the six months ended April 30, 2017 and 2016, respectively. Although research and development expenses decreased year over year, Medical Graphics remains focused on developing new products and improving existing products.

### **Amortization of Intangibles**

Amortization of acquired Medisoft intangibles was \$69,000 and \$98,000 for the six months ended April 30, 2017 and 2016, respectively. Amortization of patent costs was \$10,000 and \$20,000 for the six months ended April 30, 2017 and 2016, respectively.

The amortization of software development assets consisted of \$66,000 and \$37,000 for the six months ended April 30, 2017 and 2016, respectively, and is included in the cost of equipment revenues due to the direct relationship to equipment units sold. The Company expects the level of future amortization expense related to capitalized software development costs to increase as the Company releases to the market current projects under development.

### **Provision for Taxes**

The Company has recorded a provision for income taxes of \$188,000 and \$187,000 for the six months ended April 30, 2017 and 2016, respectively. The Company records its interim provision for income taxes based on our estimated worldwide annual effective rate for the year excluding the MGC Diagnostics Belgium S.P.R.L. loss for the period of \$234,000 and \$192,000, for the six-month periods ended April 30, 2017 and 2016, respectively, for which no tax benefit can be recognized due to future expected losses and the resulting valuation allowance related to these losses. As a result, the \$188,000 tax expense for the six months ended April 30, 2017, compared to the worldwide consolidated pre-tax income of \$157,000 (which excludes the Medisoft Belgium S.P.R.L. losses) results in an effective rate for the first six months of approximately 120%. The \$187,000 fiscal 2016 year to date expense compared to the world wide consolidated pre-tax income of \$228,000 (which includes the Medisoft Belgium S.P.R.L. loss) results in an effective rate of 82%. The difference from the federal statutory rate in fiscal 2017 and 2016 results from the effects of anticipated federal alternative minimum tax (AMT) whose credit cannot be offset due to the partial valuation allowance, state taxes expected to be paid and permanent differences whose effects are to increase the effective rate, including non-deductible meals and entertainment expense, stock-based compensation expense and expense related to reserves for uncertain tax positions. For the six-month period ended April 30, 2017, the foreign income tax expense of \$53,000 is primarily from the the increase in the valuation allowance against deferred tax assets for Medisoft Belgium.

Table of Contents

**Interest Expense**

The interest expense decrease is primarily related to the payoff of the Company's term loan on June 14, 2016 and a decrease in Medisoft non-bank related charges. Future interest cost is reduced to only the Medisoft non-bank related debt.

**Foreign Exchange**

During the six months ended April 30, 2017 and 2016, changes in the value of the Euro expressed in US dollars resulted in \$(52,000) and \$307,000 of foreign currency gain (loss), due to the changes in value of the intercompany Euro-denominated note used to partially finance the acquisition of Medisoft.

**Liquidity and Capital Resources**

The Company has financed its working capital and liquidity needs over the last several years through revenue generated by the operations of its wholly-owned Medical Graphics Corporation subsidiary.

As of April 30, 2017, the Company had cash of \$5.0 million and working capital of \$8.7 million. During the six months ended April 30, 2017, the Company generated \$1,168,000 in cash from operating activities, with \$698,000 provided by operations before changes in working capital items. Accounts receivable decreased \$1,845,000, while day sales outstanding ("DSO"), which measures how quickly receivables are collected, decreased 6 days to 59 days compared to October 31, 2016. Inventory increased by \$33,000, as days of inventory on hand increased 22 days to 92 days compared to October 31, 2016, which had benefited from higher fourth quarter revenues. Accounts payable decreased by \$874,000, due to seasonality of sales. Employee compensation accruals as of April 30, 2017 were \$258,000 lower than October 31, 2016 levels, reflecting the fiscal 2017 first quarter payments of sales commissions that had been accrued at fiscal year-end, partially offset by increased provisions for fiscal 2017 management incentive compensation and other regular period end fluctuations due to the timing of biweekly payrolls.

During the six months ended April 30, 2017, the Company used \$540,000 in cash to purchase property, equipment and intangible assets. The Company has no material commitments for capital expenditures for the remainder of fiscal 2017. The Company's fiscal 2017 operating plans include additional ongoing costs of approximately \$500,000 to develop the Company's next-generation software platform, including expensed development efforts and capitalized software development costs.

The Company's financing activities used \$2,929,000 of cash during the six months ended April 30, 2017, resulting from payment of a special cash dividend of \$0.70 per share for \$3,080,000 in the second fiscal quarter of 2017, offset by proceeds of stock option exercises and share issuances under its employee stock purchase plan.

The Company's Board of Directors will continue to periodically assess the Company's capital resources. If the Board of Directors determines that the Company's capital resources exceed the amount necessary to meet its working capital and liquidity needs, as well as to retain a reasonable cushion for contingencies and strategic opportunities, then the Company will consider various options for increasing shareholder value, including, but not limited to, purchasing its own shares in the open market and in privately negotiated transactions and paying cash dividends.

### **Litigation**

In November 2015, the Company commenced litigation in the French-speaking courts of Brussels, Belgium against the selling shareholders of Medisoft for violations of representations and warranties in the stock purchase agreement dated as of July 10, 2014 under which the Company purchased Medisoft. See "Legal Proceedings" in Part II, Item 1 of this Form 10-Q.



Table of Contents

**Forward-Looking Statements.**

The discussion above contains forward-looking statements about our future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of meaning in connection with any discussion of future operating or financial performance or business plans or prospects.

Our actual results may differ materially depending on a variety of factors including:

national and worldwide economic and capital market conditions;

continuing cost-containment efforts in hospital, clinic and office markets;

our ability to obtain revenue growth and operational synergies from our Medisoft SA subsidiary that we acquired on August 1, 2014;

our ability to complete our product operating-software development initiatives, obtain regulatory clearance for this updated software and migrate our product operating platforms to a next-generation technology;

foreign-exchange-rate-fluctuation exposure resulting from the operation of our Medisoft SA subsidiary and our increasing future international operations;

our ability to remain as qualified providers for group purchasing organizations ensuring continued access to our markets;

uncertainty or changes in medical reimbursement requirements as a result of changes in government regulation of healthcare resulting from the current administration;

reinstatement of medical device taxation related to national healthcare reform, including the 2.3% medical device tax, that was suspended for the two years beginning January 1, 2016 and ending December 31, 2017;

the success of the forced oscillation technique (“FOT”) clinical study that the Company is sponsoring;

our ability to sell our FOT product in the United States and world-wide;

our ability to realize the remaining carrying value of our SleepVirtual sleep diagnostics inventory;

our ability to successfully resolve pending litigation with the Medisoft selling shareholders;

our ability to successfully operate our business, to convert our past and continuing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and to sell these products and services into existing and new markets;

our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations, and that our cost structure will enable us to increase revenues and profitability as opportunities develop;

our ability to profitably expand our international revenue through our Medical Graphics and Medisoft distribution partners;

Table of Contents

our ability to successfully defend ourselves from product liability claims;

our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future;

our ability to realize our existing deferred tax assets in domestic and foreign jurisdictions;

our ability to successfully expand into adjunct non-core product business lines in the future without exposing ourselves to significant risk through significant inventory purchase obligations;

our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; and

our dependence on third-party vendors.

Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2016.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Our August 1, 2014 acquisition of Medisoft SA and its subsidiaries introduced considerably more exposure to currency fluctuations, which are reflected in the fiscal 2017 and 2016 losses and gains for the Euro-denominated intercompany instruments that are not regarded as permanent funding. The exposure to currency fluctuations on the remaining net assets of the acquired entities is reflected in accumulated other comprehensive loss in the consolidated balance sheet. A lower US Dollar/Euro conversion rate developed since the July 2014 funding of intra-company loans to our Belgian holding company for the acquisition of Medisoft. Further US Dollar/Euro rate reductions or increases will result in an effect on the Company's financial statements in amounts that could be material to our consolidated financial position, results of operations and cash flows.

Table of Contents

**Item 4. Controls and Procedures.**

*(a) Evaluation of Disclosure Controls and Procedures*

The Company maintains disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) that are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (ii) accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Management, with the participation of the Company's chief executive officer, Todd M. Austin, and interim chief financial officer, Jill D. Burchill, has evaluated the effectiveness of the design and operation of the disclosure controls and procedures, as defined in Rules 13a-15(e) under the Securities Exchange Act of 1934, as of the end of the period covered by this report. Based on that evaluation and because of the material weakness in internal control over financial reporting disclosed in our Annual Report on Form 10-K, management concluded that the Company's disclosure controls and procedures are not effective to ensure that information required to be disclosed in the reports that the Company files under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that the disclosure controls are also not effective to ensure that information required to be disclosed in the Company's Exchange Act reports is accumulated and communicated to management, including the chief executive officer and principal accounting officer, to allow timely decisions regarding required disclosure.

*(b) Changes in Internal Controls*

There have been no changes in internal control over financial reporting that occurred during the quarter ended April 30, 2017 that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting. As disclosed in our Annual Report on Form 10-K for the year ended October 31, 2016, we concluded that our internal control over financial reporting was not effective, and as a result, the three significant deficiencies that we identified, when evaluated in aggregate, resulted in a material weakness in internal controls.

The identified material weakness arose as a result of significant deficiencies in management's processes and controls over the development of management's estimations of valuation reserves for allowance for doubtful accounts and inventory valuation reserves that occurred during the fourth quarter of 2016:

1. We concluded that controls surrounding the gathering, interpretation and evaluation of supporting documentation for SleepVirtual sales forecasts were ineffective in determining the appropriate value of the SleepVirtual inventory on hand.
  
2. We concluded that Company policies and procedures in place surrounding demonstration inventory were not adequately followed or reviewed to ensure the demonstration inventory units were monitored for the amount of time they were deployed for selling activities. The aging of some units required an inventory valuation reserve to properly reflect the estimated net realizable value of the demonstration units in inventory.
  
3. We concluded that the controls surrounding estimation of collectability of aged international accounts receivable were not adequate to establish the correct reserve for a specific customer as of October 31, 2016.

Table of Contents

The material weakness resulted in misstatements in the recorded amount of inventory valuation reserves and allowance for doubtful accounts reserves that were corrected in the fourth quarter of 2016 prior to issuance of the Company's consolidated financial statements. We concluded that a reasonable possibility existed that a material misstatement in the Company's consolidated financial statements would not have been prevented or detected on a timely basis.

**Remediation Plan for Material Weaknesses in Internal Control over Financial Reporting**

During our 2017 fiscal quarter beginning February 1, 2017, we began

to implement the following remediation plan to address the material weakness described above:

- Strengthen the quarterly monitoring of our international open accounts receivable aging to determine an appropriate allowance for uncollectable accounts,
- Strengthen oversight of unit sales projections on inventory purchased from third party manufacturers for resale and critically assess the reasonableness of assumptions for expected selling prices and gross margins used to determine the appropriateness of lower-of-cost-or-market reserves,
- Establish structured training with sales and sales support personnel on existing Company corporate policies and procedures to manage and value all Company demonstration inventory, and
- Conduct a thorough review of demonstration inventory aging to ensure appropriate valuation reserves have been established.

Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, will be or have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is also based in part upon specific assumptions about the likelihood of future events. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies or procedures may deteriorate.

Table of Contents

## **PART II – OTHER INFORMATION**

### **Item 1. Legal Proceedings.**

The Company is subject to claims and lawsuits that have been filed in the ordinary course of business. From time to time, the Company brings suit against others to enforce patent rights or to collect debts in the ordinary course of business. The Company is not subject to any pending litigation except as set forth below.

#### **MGC Diagnostics Corporation v. Mr. Guy Martinot and Dr. Jean-Benoit Martinot**

In November 2015, the Company commenced litigation in the French-speaking courts of Brussels, Belgium against the selling shareholders of Medisoft for violations of representations and warranties in the stock purchase agreement dated as of July 10, 2014 under which the Company purchased Medisoft. The Company alleged that these violations resulted in Company damages of approximately €985,400 (\$1,084,000). In May 2015, the Company received payment of €406,700 (\$447,000) with respect to these alleged violations pursuant to a bank-guaranteed contractual escrow fund and has reflected that payment on its books and records. On May 30, 2016, the defendant selling shareholders filed an answer and asserted a counterclaim against the Company seeking to recover the €406,700 that was paid to the Company in May 2015 and legal costs. The Company continues to believe the Medisoft selling shareholders are liable to it for violations of representations and warranties in the stock purchase agreement and intends to continue to pursue this matter. The Company has not accrued any losses related to the litigation or accrued any related legal costs it has not yet incurred. The Company currently expects that this litigation process may continue until the fall of 2018.

### **Item 1A. Risk Factors.**

We described the most significant risk factors applicable to the Company in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended October 31, 2016. We believe there have been no material changes to the risk factors disclosed in that Annual Report on Form 10-K.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

### **Item 3. Default Upon Senior Securities.**

None.

#### **Item 4. Mine Safety Disclosure.**

None.

#### **Item 5. Other Information.**

##### **Lease Amendment**

As described in Note 12 of the Notes to Consolidated Financial Statements, on May 5, 2017, the Company agreed to extend the lease for the Saint Paul, Minnesota manufacturing and office facilities through December 31, 2018. The agreement contains a Company right to extend the lease through December 31, 2019.

24

---



Table of Contents**Distribution Agreement Amendment**

On August 17, 2012, the Company entered into a five-year worldwide distribution agreement with Restech Srl to distribute Restech's forced oscillation technique (“FOT”) products. On February 14, 2017 the Company and Restech amended the agreement, which now expires on June 30, 2018. The amended agreement eliminates any future Company purchase obligations and retains MGC Diagnostics' exclusivity in all countries except Italy, Russia, Albania, Kosovo and Macedonia. The Company has the right to negotiate a new multi-year agreement prior to March 15, 2018. In the event that the current agreement terminates on June 30, 2018, the Company will retain exclusivity to distribute FOT products in the United States and Canada through September of 2019 and will retain its international exclusivity through March of 2019.

In connection with the amended agreement, the Company and Restech agreed to collaborate on a clinical study to evaluate the diagnostic accuracy of the FOT products to detect lung function abnormalities. The study is designed to compare the diagnostic accuracy of the RESMON PRO FULL to the diagnostic accuracy of spirometry to detect a lung function anomaly (obstructive or restrictive respiratory disease) in a prospective and consecutive cohort of subjects obtaining pulmonary function tests (“PFT”) in PFT labs. As a secondary objective, the study will aim to compare the diagnostic accuracy of at least one, or a combination, of the parameters provided by the Resmon PRO FULL to the diagnostic accuracy of spirometry to detect a significant response to a bronchodilator. MGC Diagnostics will sponsor the study and Restech Srl will conduct the study. The Company expects the clinical study to generate evidence that would (i) allow the Company to obtain additional FDA clearance and (ii) result in health care professionals using FOT products in a broader range of applications.

The Company expects worldwide enrollment to begin in the calendar year 2017 third quarter and expects the study will conclude during the third or fourth quarter of calendar 2018. The study will include subjects ranging from age three to adulthood. MGC Diagnostics expects its total investment for the clinical study will not exceed \$500,000, including a series of Company payments to Restech aligned to project milestones. The Company made an initial €87,000 payment to Restech in the fiscal 2017 second quarter.

**Item 6. Exhibits.**

10.1<sup>1</sup> Fifth Addendum dated May 5, 2017 to lease with respect to premises at 350 Oak Grove Parkway, Vadnais Heights, Minnesota.

31.1 Certifications of Chief Executive Officer pursuant to 13a-14 and 15d-14 of the Exchange Act.

31.2 Certifications of Chief Financial Officer pursuant to 13a-14 and 15d-14 of the Exchange Act.

32. Certifications pursuant to 18 U.S.C. §1350.

101\* The following materials from our Quarterly Report on Form 10-Q for the quarter ended April 30, 2017 formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Notes to Consolidated Financial Statements and (vi) document and entity information.

Pursuant to Rule 406T of Regulation S-T, the XBRL related information in Exhibit 101 to this Report on Form 10-Q shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the \*liability of that section, and shall not be deemed part of a registration statement, prospectus or other document filed under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filings.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MGC DIAGNOSTICS CORPORATION  
(Registrant)

June 13, 2017

By: /s/ Todd M. Austin  
Todd M. Austin  
Chief Executive Officer

June 13, 2017

By: /s/ Larry R. Degen  
Larry R. Degen  
Chief Accounting Officer